GRAd-COV2, a Gorilla Adenovirus-Based Candidate Vaccine against COVID-19, Is Safe and Immunogenic in Younger and Older Adults

The authors described a COVID-19 vaccine based on a replication-defective gorilla adenovirus expressing the stabilized pre-fusion SARS-CoV-2 spike protein, named GRAd-COV2.